CKM

CKM encodes the muscle-type (M) subunit of creatine kinase, a central enzyme in cellular energy homeostasis in skeletal and cardiac muscle that catalyzes the reversible transfer of phosphate between ATP and creatine. The tissue-form homodimer CK-MM3, upon release from injured myocardium or exercised skeletal muscle, undergoes sequential carboxypeptidase-mediated post-translational conversion in the circulation to MM2 and then MM1, generating a time-dependent isoform ratio that reflects the kinetics of muscle damage and reperfusion (PMID:2686906, PMID:3815799). CKM expression is transcriptionally regulated in a muscle-specific manner, is positively controlled by insulin signaling in the heart, and is selectively impaired in dystrophic muscle under innervated/contracting conditions (PMID:1887884, PMID:3613854). Beyond its enzymatic role, CKM functions in myoblast biology by inhibiting proliferation and promoting differentiation, and circulating CK-MM levels are further modulated by autoantibody-mediated immune complex formation that accelerates its clearance (PMID:37508090, PMID:16810680).

1. 1987 Medium

   Whether CKM expression was selectively affected in muscular dystrophy was unknown; innervated contracting DMD muscle fibers showed specific impairment of CK-MM accumulation while other muscle isozymes were unaffected, establishing that the dystrophic defect selectively targets CKM and requires innervation/contraction to manifest.

   Evidence Long-term innervated contracting cultured muscle fibers from DMD patients with CK-MM isozyme activity assay

   PMID:3613854

   Open questions at the time

   • Mechanism by which dystrophin absence selectively impairs CKM expression or stability is unknown
   • Not tested in animal models of DMD
   • Whether impairment is transcriptional, translational, or due to protein instability was not resolved
2. 1987 Medium

   The kinetics of CK-MM isoform conversion after myocardial infarction and reperfusion were undefined; serial sampling showed that the tissue isoform MM3 peaks earlier than total CK or CK-MB and that the MM3/MM1 ratio shifts even more rapidly during successful reperfusion, establishing isoform conversion kinetics as a mechanistic readout of myocardial necrosis timing.

   Evidence Serial blood sampling with anion-exchange chromatography and high-voltage electrophoresis in 35 AMI patients including thrombolysis subgroups

   PMID:3815799

   Open questions at the time

   • Identity of the specific carboxypeptidase(s) responsible for in vivo conversion was not definitively established
   • Clearance kinetics of individual isoforms were not measured
3. 1988 Medium

   Whether sex differences in post-exercise CK elevation were isoform-specific was unknown; isoenzyme profiling after treadmill exercise revealed that the sex-linked difference in plasma CK is attributable specifically to CK-MM (not CK-BB), with males showing ~6-fold greater CK-MM release than females.

   Evidence CK isoenzyme profiling of plasma and tissue homogenates before and after treadmill exercise in male and female rats

   PMID:3174399

   Open questions at the time

   • Hormonal or membrane-integrity mechanism underlying sex-differential CK-MM leakage was not identified
   • Not confirmed in human subjects
4. 1989 Medium

   The biochemical basis of CK-MM isoform heterogeneity was clarified: the tissue isoform MM3 is converted to MM2 and MM1 by carboxypeptidase action in the circulation, as demonstrated by differential monoclonal antibody inhibition, metal dependence (EDTA sensitivity), and heat lability of MM3.

   Evidence Monoclonal antibody immunoinhibition, EDTA chelation, and heat-lability assays of CK-MM isoforms; anion-exchange chromatography of serial AMI patient samples

   PMID:1762189 PMID:2686906

   Open questions at the time

   • Specific carboxypeptidase isoform responsible was not identified
   • Structural basis of how C-terminal cleavage alters charge and activity was not resolved
5. 1991 Medium

   Whether CKM expression is directly regulated by insulin was untested; insulin injection in diabetic rats restored CK-M mRNA from ~47% of control to normal levels within 12 hours, establishing CKM as an insulin-responsive gene in the heart.

   Evidence Northern blot quantitation of CK-M mRNA in streptozotocin-diabetic rat hearts after insulin administration

   PMID:1887884

   Open questions at the time

   • Whether regulation is transcriptional or post-transcriptional was not distinguished
   • Signaling pathway (PI3K, MAPK, etc.) mediating insulin effect was not identified
   • Not confirmed in human cardiac tissue
6. 1991 Medium

   CKM was investigated as a candidate gene for myotonic dystrophy due to its chromosomal proximity; sequencing of CKM cDNA from DM patient muscle excluded coding-region mutations as the cause, helping to resolve that CKM is not the DM disease gene.

   Evidence Full cDNA sequencing of CKM from DM patient skeletal muscle

   PMID:2016086

   Open questions at the time

   • Regulatory region variants in CKM were not assessed
   • Whether CKM expression levels are altered in DM was not quantified
7. 2006 Medium

   Whether circulating CK-MM is subject to immune regulation was unknown; CK-MM autoantibodies were shown to form immune complexes with CK-MM and to accelerate its clearance from the circulation by 11–32% in vivo, establishing an immunological mechanism that modulates serum CK-MM levels.

   Evidence ELISA for CK-MM autoantibodies; protein A-sepharose pulldown for immune complexes; in vivo mouse antibody administration experiment

   PMID:16810680

   Open questions at the time

   • Fc receptor or reticuloendothelial mechanism of immune complex clearance was not defined
   • Clinical significance for diagnostic CK interpretation in autoimmune patients not established
8. 2023 Medium

   Beyond its enzymatic role, CKM's function in myoblast fate decisions was uncharacterized; overexpression in primary myoblasts inhibited proliferation and promoted differentiation while knockdown altered myogenesis-associated gene networks, establishing CKM as a functional regulator of myogenesis.

   Evidence Overexpression and RNAi in chicken primary myoblasts with proliferation, apoptosis, differentiation assays and RNA-seq transcriptomics

   PMID:37508090

   Open questions at the time

   • Mechanism by which CKM enzymatic activity (or a non-catalytic function) regulates proliferation/differentiation is unknown
   • Not validated in mammalian myoblasts
   • Downstream signaling pathways were identified transcriptomically but not functionally validated

• Key unresolved questions include the identity of the specific carboxypeptidase(s) that convert CK-MM3 to MM1 in vivo, the signaling pathway through which insulin regulates CKM transcription, and whether CKM's role in myoblast differentiation is catalytic or reflects a moonlighting function.
• No structural model of the CK-MM isoform conversion site
• Non-enzymatic functions of CKM in differentiation have not been mechanistically dissected
• In vivo genetic loss-of-function models (knockout) in mammals are poorly characterized in the literature